10 newer rulings cite the same tariff codes.

Classification can shift over time. Review the more recent rulings below before relying on this one.

L81011 L8 Ruling Active

The tariff classification of Sorafenib (CAS-284461-73-0), imported in bulk form, from France

Issued December 13, 2004 by U.S. Customs and Border Protection.

Cite this ruling

Copies to clipboard

L8 L81011 (December 13, 2004)

Tariff classification

HTS codes: 2933.39.4100

Headings: 2933

Product description

According to an article found on the World Wide Web, the subject product, Sorafenib (aka BAY 43-9006), is currently in Phase III clinical trials and has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic renal-cell carcinoma. Perusal of the ClinicalTrials.gov. website indicates that patients are being recruited for participation in clinical trials to evaluate Sorafenib’s efficacy in the treatment of several other types of malignancies.

CBP rationale

The applicable subheading for Sorafenib, imported in bulk form, will be 2933.39.4100, Harmonized Tariff of the United States (HTS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: Other: Drugs: Other.

Full text

NY L81011 December 13, 2004 CLA-2-29:RR:NC:2:238 L81011 CATEGORY: Classification TARIFF NO.: 2933.39.4100 Mr. Joseph J. Chivini Austin Chemical Company, Inc. 1565 Barclay Boulevard Buffalo Grove, IL 60089 RE: The tariff classification of Sorafenib (CAS-284461-73-0), imported in bulk form, from France Dear Mr. Chivini: In your letter dated November 17, 2004, you requested a tariff classification ruling. According to an article found on the World Wide Web, the subject product, Sorafenib (aka BAY 43-9006), is currently in Phase III clinical trials and has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic renal-cell carcinoma. Perusal of the ClinicalTrials.gov. website indicates that patients are being recruited for participation in clinical trials to evaluate Sorafenib’s efficacy in the treatment of several other types of malignancies. The applicable subheading for Sorafenib, imported in bulk form, will be 2933.39.4100, Harmonized Tariff of the United States (HTS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: Other: Drugs: Other.” The rate of duty will be 6.5 percent ad valorem. The rate of duty will remain the same in 2005. At the present time, Sorafenib is not listed in the Pharmaceutical Appendix to the Tariff Schedule. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 1-888-443-6332. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Follow L81011

Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.

One email per day at most. Confirm your address once, unsubscribe anytime.

Searching CBP rulings the smart way

Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.